Ads
related to: nuplazid- $0 Co-Pay For Patients
Find Support Programs Including A
$0 Co-Pay Program For Your Patients
- Ordering And Billing
Review Ordering And Billing
Information For Treatment.
- FDA-Approved Treatment
Find Information And Resources On
This FDA-Approved Treatment Option.
- Clinical Efficacy Data
Find Information About A Clinical
Study For This Treatment Option.
- Find A Representative
Find A Local Representative To Gain
Access To More Information.
- Treatment Science
Learn About The Science Behind This
Hemophilia A Treatment Option.
- $0 Co-Pay For Patients
Search results
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
Zacks via Yahoo Finance· 5 months agoAcadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However,...
Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern
Zacks via Yahoo Finance· 2 years agoAcadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions...
Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio
Zacks via Yahoo Finance· 1 year agoAcadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since...
Acadia (ACAD) Rises 35% on Positive Patent Ruling for Nuplazid
Zacks via Yahoo Finance· 6 months agoAcadia (ACAD) announces a ruling from the U.S. District Court in Delaware, strongly in favor of the...
Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now
Zacks via Yahoo Finance· 8 months agoSan Diego, CA-based Acadia Pharmaceuticals Inc. ACAD is a commercial biopharmaceutical company...
Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug
Investor's Business Daily· 6 months agoAcadia Pharmaceuticals notched a win in a patent battle Wednesday pertaining to its Parkinson's...
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
Investor's Business Daily· 3 months agoAcadia stock crashed to an 11-month low Tuesday after an outsized placebo effect torpedoed the...
ACADIA Pharmaceuticals Inc. Reports Record Revenues in Q3 2023
GuruFocus.com via Yahoo Finance· 7 months agoACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported record revenues in Q3 2023, driven by the strong...
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
Zacks via Yahoo Finance· 2 years agoAn FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating...
Acadia (ACAD) Q4 Earnings Miss, Nuplazid Sales Boost Revenues
Zacks via Yahoo Finance· 1 year agoAcadia Pharmaceuticals (ACAD) reports mixed results for the fourth quarter of 2022, recording...
Ads
related to: nuplazid